STAC3 as a poor prognostic biomarker in renal clear cell carcinoma: relationship with immune infiltration: Am J Cancer Res. 2024; 14(7): 3294-3316 | Synapse
March 3, 2026
STAC3 as a poor prognostic biomarker in renal clear cell carcinoma: relationship with immune infiltration: Am J Cancer Res. 2024; 14(7): 3294-3316
Puntos clave
STAC3 serves as a poor prognostic biomarker for renal clear cell carcinoma, affecting patient outcomes.
Higher levels of immune infiltration correlate with poor prognostic indications linked to STAC3 expression.
This observational analysis assessed the relationship of STAC3 with immune infiltration in renal clear cell carcinoma cases.
These findings suggest that STAC3 may influence treatment strategies, though further validation is warranted.
Resumen
This corrects the article on p. 3294 in vol. 14, PMID: 39113874..